3 Stocks Dragging The Health Services Industry Downward

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 22 points (0.1%) at 15,424 as of Tuesday, Sept. 24, 2013, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,875 issues advancing vs. 1,030 declining with 132 unchanged.

The Health Services industry currently sits up 0.5% versus the S&P 500, which is up 0.2%. A company within the industry that fell today was Intuitive Surgical ( ISRG), up 1.0%.

TheStreet would like to highlight 3 stocks pushing the industry lower today:

3. BioScrip ( BIOS) is one of the companies pushing the Health Services industry lower today. As of noon trading, BioScrip is down $1.41 (-13.5%) to $9.00 on heavy volume. Thus far, 3.8 million shares of BioScrip exchanged hands as compared to its average daily volume of 864,300 shares. The stock has ranged in price between $8.83-$10.58 after having opened the day at $10.39 as compared to the previous trading day's close of $10.41.

BioScrip, Inc. provides home infusion and other home care services, and pharmacy benefit management (PBM) services in the United States. It operates in three segments: Infusion Services, Home Health Services, and PBM Services. BioScrip has a market cap of $750.3 million and is part of the health care sector. Shares are up 2.8% year to date as of the close of trading on Monday. Currently there are 6 analysts that rate BioScrip a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates BioScrip as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and weak operating cash flow. Get the full BioScrip Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

2. As of noon trading, Covidien ( COV) is down $0.40 (-0.6%) to $62.21 on light volume. Thus far, 704,875 shares of Covidien exchanged hands as compared to its average daily volume of 2.4 million shares. The stock has ranged in price between $62.13-$62.60 after having opened the day at $62.55 as compared to the previous trading day's close of $62.61.

Covidien plc develops, manufactures, and sells healthcare products for use in clinical and home settings worldwide. Covidien has a market cap of $29.0 billion and is part of the health care sector. Shares are up 9.2% year to date as of the close of trading on Monday. Currently there are 13 analysts that rate Covidien a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Covidien as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, reasonable valuation levels, largely solid financial position with reasonable debt levels by most measures, notable return on equity and increase in stock price during the past year. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Covidien Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

1. As of noon trading, Baxter International ( BAX) is down $0.42 (-0.6%) to $71.42 on average volume. Thus far, 1.1 million shares of Baxter International exchanged hands as compared to its average daily volume of 2.6 million shares. The stock has ranged in price between $71.28-$72.00 after having opened the day at $71.80 as compared to the previous trading day's close of $71.84.

Baxter International Inc., through its subsidiaries, develops, manufactures, and markets products for people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. Baxter International has a market cap of $38.9 billion and is part of the health care sector. Shares are up 7.4% year to date as of the close of trading on Monday. Currently there are 12 analysts that rate Baxter International a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Baxter International as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, expanding profit margins, solid stock price performance and notable return on equity. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Baxter International Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you are interested in one of these 5 stocks, ETFs may be of interest. Investors who are bullish on the health services industry could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health services industry could consider ProShares Ultra Short Health Care ( RXD).
null

If you liked this article you might like

Stick to Small, Fast Trades Until the Fed's out of the Way

Stick to Small, Fast Trades Until the Fed's out of the Way

These 5 Stocks Under $10 Could Light Up Soon

These 5 Stocks Under $10 Could Light Up Soon

5 Stocks Insiders Love Right Now

5 Stocks Insiders Love Right Now

BioScrip (BIOS) Stock: Weak On High Volume Today

BioScrip (BIOS) Stock: Weak On High Volume Today

5 Stocks Under $10 Set to Soar

5 Stocks Under $10 Set to Soar